Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Ablynx N.V.

Sanofi Continues Hunt For External Innovation With Skyhawk Deal

Deal Snapshot: A lot of the French drug maker’s interest has focused on biologics, but the Skyhawk deal shows it has maintained a keen interest in innovative small molecules as well.

Deals Business Strategies

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Sanofi's Nestle talked to Scrip about the company's early pipeline, the emerging technologies he thinks are most promising and tapping external innovation.

Research & Development Leadership

Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds

Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

Financing Innovation

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.

New Science Leadership
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Ablynx NV
UsernamePublicRestriction

Register